Lung volume quantified by MRI reflects extracellular-matrix deposition and altered pulmonary function in bleomycin models of fibrosis: Effects of SOM230

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 306, Issue 12, 2014, Pages

  Egger, Christine ^a,b   Gérard, Christelle ^a   Vidotto, Nella ^a   Accart, Nathalie ^a   Cannet, Catherine ^a   Dunbar, Andrew ^a   Tigani, Bruno ^a   Piaia, Alessandro ^a   Jarai, Gabor ^c   Jarman, Elizabeth ^c   Schmid, Herbert A ^a   Beckmann, Nicolau ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Bleomycin; Compliance; Elastance; Fibrosis; Imaging; Magnetic resonance imaging (MRI); SOM230; Ultrashort echo time (UTE)

Indexed keywords

BLEOMYCIN; COLLAGEN; HYDROXYPROLINE; OVALBUMIN; PASIREOTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREATHING PATTERN; CONTROLLED STUDY; DRUG EFFECT; EXPIRATORY FLOW; EXTRACELLULAR MATRIX; HISTOPATHOLOGY; INSPIRATORY CAPACITY; LUNG COMPLIANCE; LUNG FIBROSIS; LUNG FUNCTION; LUNG INJURY; LUNG VOLUME; LUNG WEIGHT; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; TIDAL VOLUME;

BLEOMYCIN; COMPLIANCE; ELASTANCE; FIBROSIS; IMAGING; MAGNETIC RESONANCE IMAGING (MRI); SOM230; ULTRASHORT ECHO TIME (UTE);

ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; EXTRACELLULAR MATRIX; HYDROXYPROLINE; INFLAMMATION; LUNG; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED C57BL; PULMONARY FIBROSIS; RATS; RATS, SPRAGUE-DAWLEY; SOMATOSTATIN;

EID: 84902687881     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00027.2014     Document Type: Article

References (60)

1. Ask K, Labiris R, Farkas L, Moeller A, Froese A, Farncombe T, McClelland GB, Inman M, Gauldie J, Kolb MR. Comparison between conventional and "clinical" assessment of experimental lung fibrosis. J Transl Med 6: 16, 2008.
2. Babin AL, Cannet C, Gérard C, Wyss D, Page CP, Beckmann N. Noninvasive assessment of bleomycin-induced lung injury and the effects of short-term glucocorticosteroid treatment in rats using MRI. J Magn Reson Imaging 33: 603-614, 2011.
3. Babin AL, Cannet C, Gérard C, Saint-Mezard P, Page CP, Sparrer H, Matsuguchi T, Beckmann N. Bleomycin-induced lung injury in mice investigated by MRI: model assessment for target analysis. Magn Reson Med 67: 499-509, 2012.
4. Beckmann N, Tigani B, Ekatodramis D, Borer R, Mazzoni L, Fozard JR. Pulmonary edema induced by allergen challenge in the rat: noninvasive assessment by magnetic resonance imaging. Magn Reson Med 45: 88-95, 2001.
5. Blum RH, Carter SK, Agre K. A clinical review of bleomycin-a new antineoplastic agent. Cancer 31: 903-914, 1973.
6. Borie R, Fabre A, Prost F, Marchal-Somme J, Lebtahi R, Marchand-Adam S, Aubier M, Soler P, Crestani B. Activation of somatostatin receptors attenuates pulmonary fibrosis. Thorax 63: 251-258, 2008.
7. Card JW, Voltz JW, Carey MA, Bradbury JA, Degraff LM, Lih FB, Bonner JC, Morgan DL, Flake GP, Zeldin DC. Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis. Am J Respir Cell Mol Biol 37: 300-308, 2007.
8. Cesarovic N, Nicholls F, Rettich A, Kronen P, Hässig M, Jirkof P, Arras M. Isoflurane and sevoflurane provide equally effective anesthesia in laboratory mice. Lab Anim 44: 329-336, 2010.
9. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 33: 9-13, 2005.
10. Corbel M, Caulet-Maugendre S, Germain N, Molet S, Lagente V, Boichot E. Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat. J Pathol 193: 538-545, 2001.
11. Crestani B, Chapron J, Wallaert B, Bergot E, Delaval P, Israel-Biet D, Lacronique J, Monnet I, Reynaud-Gaubert M, Tazi A, Lebtahi R, Debray MP, Brauner M, Dehoux M, Dornic Q, Aubier M, Mentré F, Duval X. Octreotide treatment of idiopathic pulmonary fibrosis: a proofof-concept study. Eur Respir J 39: 772-775, 2012.
12. Dackor RT, Cheng J, Voltz JW, Card JW, Ferguson CD, Garrett RC, Bradbury JA, DeGraff LM, Lih FB, Tomer KB, Flake GP, Travlos GS, Ramsey RW Jr, Edin ML, Morgan DL, Zeldin DC. Prostaglandin E2 protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction. Am J Physiol Lung Cell Mol Physiol 301: L645-L655, 2011.
13. Degryse AL, Tanjore H, Xu XC, Polosukhin VV, Jones BR, McMahon FB, Gleaves LA, Blackwell TS, Lawson WE. Repetitive intratracheal bleomycin models several features of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 299: L442-L452, 2010.
14. Dolhnikoff M, Mauad T, Ludwig MS. Extracellular matrix and oscillatory mechanics of rat lung parenchyma in bleomycin-induced fibrosis. Am J Respir Crit Care Med 160: 1750-1757, 1999.
15. Ebihara T, Venkatesan N, Tanaka R, Ludwig MS. Changes in extracellular matrix and tissue viscoelasticity in bleomycin-induced lung fibrosis. Temporal aspects. Am J Respir Crit Care Med 162: 1569-1576, 2000.
16. Egger C, Cannet C, Gérard C, Jarman E, Jarai G, Feige A, Suply T, Micard A, Dunbar A, Tigani B, Beckmann N. Administration of bleomycin via the oropharyngeal aspiration route leads to sustained lung fibrosis in mice and rats as quantified by UTE-MRI and histology. PLoS One 8: e63432, 2013.
17. Eikermann M, Malhotra A, Fassbender P, Zaremba S, Jordan AS, Gautam S, White DP, Chamberlin NL. Differential effects of isoflurane and propofol on upper airway dilator muscle activity and breathing. Anesthesiology 108: 897-906, 2008.
18. Feelders RA, de Herder WW, Neggers SJ, van der Lely AJ, Hofland LJ. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors. Drugs Today (Barc) 49: 89-103 (2013.
19. Ferreira JC, Benseñor FE, Rocha MJ, Salge JM, Harris RS, Malhotra A, Kairalla RA, Kacmarek RM, Carvalho CR. A sigmoidal fit for pressure-volume curves of idiopathic pulmonary fibrosis patients on mechanical ventilation: clinical implications. Clinics (Sao Paulo) 66: 1157-1163, 2011.
20. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 345: 517-525, 2001.
21. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol 65: 81-94, 1991.
22. Hunninghake GW, Schwarz MI. Does current knowledge explain the pathogenesis of idiopathic pulmonary fibrosis? A perspective. Proc Am Thorac Soc 4: 449-452, 2007.
23. Izbicki G, Segel MJ, Christensen TG, Conner MW, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol 83: 111-119, 2002.
24. Jacob RE, Amidan BG, Soelberg J, Minard KR. In vivo MRI of altered proton signal intensity and T2 relaxation in a bleomycin model of pulmonary inflammation and fibrosis. J Magn Reson Imaging 31: 1091-1099, 2010.
25. Karmouty-Quintana H, Cannet C, Zurbruegg S, Blé FX, Fozard JR, Page CP, Beckmann N. Bleomycin-induced lung injury assessed noninvasively and in spontaneously breathing rats by proton MRI. J Magn Reson Imaging 26: 941-949, 2007.
26. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med 157: 1301-1315, 1998.
27. Lazo JS, Sebti SM. Bleomycin. Cancer Chemother Biol Response Modif 17: 40-45, 1997.
28. Lebtahi R, Moreau S, Marchand-Adam S, Debray MP, Brauner M, Soler P, Marchal J, Raguin O, Gruaz-Guyon A, Reubi JC, Le Guludec D, Crestani B. Increased uptake of 111In-octreotide in idiopathic pulmonary fibrosis. J Nucl Med 47, 1281-1287, 2006.
29. Leslie KO. Pathology of interstitial lung disease. Clin Chest Med 25: 657-703, vi, 2004.
30. Manali ED, Moschos C, Triantafillidou C, Kotanidou A, Psallidas I, Karabela SP, Roussos C, Papiris S, Armaganidis A, Stathopoulos GT, Maniatis NA. Static and dynamic mechanics of the murine lung after intratracheal bleomycin. BMC Pulm Med 11: 33, 2011.
31. Mansoor JK, Hyde DM, Schelegle ES. Contribution of vagal afferents to breathing pattern in rats with lung fibrosis. Respir Physiol 108: 45-61, 1997.
32. Merin RG, Brown JL. Anesthesiology. N Engl J Med 338: 684, 1998.
33. Milton PL, Dickinson H, Jenkin G, Lim R. Assessment of respiratory physiology of C57BL/6 mice following bleomycin administration using barometric plethysmography. Respiration 83: 253-266, 2012.
34. Mirfazaelian A, Fisher JW. Organ growth functions in maturing male Sprague-Dawley rats based on a collective database. J Toxicol Environ Health A 70: 1052-1063, 2007.
35. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40: 362-382, 2008.
36. Moore BB, Hogaboam CM. Murine models of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 294: L152-L160, 2008.
37. Mouratis MA, Aidinis V. Modeling pulmonary fibrosis with bleomycin. Curr Opin Pulm Med 17: 355-361, 2011.
38. Nava S, Rubini F. Lung and chest wall mechanics in ventilated patients with end stage idiopathic pulmonary fibrosis. Thorax 54: 390-395, 1999.
39. Nettelbladt O, Scheynius A, Bergh J, Tengblad A, Hällgren R. Alveolar accumulation of hyaluronan and alveolar cellular response in bleomycin-induced alveolitis. Eur Respir J 4: 407-414, 1991.
40. Ngeow J, Tan IB, Kanesvaran R, Tan HC, Tao M, Quek R, Lim ST. Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma. Ann Hematol 90: 67-72, 2011.
41. Pivonello R, Petersenn S, Newell-Price J, Findling J, Gu F, Maldonado M, Trovato A, Hughes G, Salgado L, Lacroix A, Schopohl J, Biller B; The Pasireotide B2305 Study Group. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. Clin Endocrinol (Oxf). 2014 Feb 17. doi: 10.1111/cen.12431.
42. Quintana HK, Cannet C, Zurbruegg S, Blé FX, Fozard JR, Page CP, Beckmann N. Proton MRI as a noninvasive tool to assess elastaseinduced lung damage in spontaneously breathing rats. Magn Reson Med 56: 1242-1250, 2006.
43. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/ JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011.
44. Schmid HA, Brueggen J. Effects of somatostatin analogs on glucose homeostasis in rats. J Endocrinol 212: 49-60, 2012.
45. Schmid HA, Schoeffter P. Functional activity of the multiligand analog SOM230 at human recombinant somatostatin receptor subtypes supports its usefulness in neuroendocrine tumors. Neuroendocrinology 80, Suppl 1: 47-50, 2004.
46. Scotton CJ, Chambers RC. Bleomycin revisited: towards a more representative model of IPF? Am J Physiol Lung Cell Mol Physiol 299: L439-L441, 2010.
47. Sleijfer S. Bleomycin-induced pneumonitis. Chest 120: 617-624, 2001.
48. Snider GL, Hayes JA, Korthy AL. Chronic interstitial pulmonary fibrosis produced in hamsters by endotracheal bleomycin: pathology and stereology. Am Rev Respir Dis 117: 1099-1108, 1978.
49. Strobel K, Hoerr V, Schmid F, Wachsmuth L, Löffler B, Faber C. Early detection of lung inflammation: exploiting T1-effects of iron oxide particles using UTE MRI. Magn Reson Med 68: 1924-1931, 2012.
50. Takahashi M, Togao O, Obara M, van Cauteren M, Ohno Y, Doi S, Kuro-o M, Malloy C, Hsia CC, Dimitrov I. Ultra-short echo time (UTE) MR imaging of the lung: comparison between normal and emphysematous lungs in mutant mice. J Magn Reson Imaging 32: 326-333, 2010.
51. Takemasa A, Ishii Y, Fukuda T. A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice. Eur Respir J 40: 1475-1482, 2012.
52. Thrall RS, McCormick JR, Jack RM, McReynolds RA, Ward PA. Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol 95: 117-130, 1979.
53. Thrall RS, Swendsen CL, Shannon TH, Kennedy CA, Frederick DS, Grunze MF, Sulavik SB. Correlation of changes in pulmonary surfactant phospholipids with compliance in bleomycin-induced pulmonary fibrosis in the rat. Am Rev Respir Dis 136: 113-118, 1987.
54. Tigani B, Schaeublin E, Sugar R, Jackson AD, Fozard JR, Beckmann N. Pulmonary inflammation monitored noninvasively by MRI in freely breathing rats. Biochem Biophys Res Commun 292: 216-221, 2002.
55. Ueda Y, Saito A, Fukuoka Y, Yamashiro Y, Ikeda Y, Taki H, Yasuda T, Saikawa I. Interactions of beta-lactam antibiotics and antineoplastic agents. Antimicrob Agents Chemother 23: 374-378, 1983.
56. van Echteld CJ, Beckmann N. A view on imaging in drug research and development for respiratory diseases. J Pharmacol Exp Ther 337: 335-349, 2011.
57. Verbeken EK, Cauberghs M, Lauweryns JM, Van de Woestijne KP. Structure and function in fibrosing alveolitis. J Appl Physiol 76: 731-742, 1994.
58. Voltz JW, Card JW, Carey MA, Degraff LM, Ferguson CD, Flake GP, Bonner JC, Korach KS, Zeldin DC. Male sex hormones exacerbate lung function impairment after bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 39: 45-52, 2008.
59. Westergren-Thorsson G, Hernnäs J, Särnstrand B, Oldberg A, Heinegård D, Malmström A. Altered expression of small proteoglycans, collagen, and transforming growth factor-beta 1 in developing bleomycininduced pulmonary fibrosis in rats. J Clin Invest 92: 632-637, 1993.
60. Zurek M, Bessaad A, Cieslar K, Crémillieux Y. Validation of simple and robust protocols for high-resolution lung proton MRI in mice. Magn Reson Med 64: 401-407, 2010.